Table 1.
Year | Author | PatientNo. | Size (cm)1 | FU (mo)2 | LTP (%)3 | New recur (%)4 | Major Cx (%)5 |
Overall survival (%) |
Median survival(mo) | Evidence6 | ||
1 yr | 3 yr | 5 yr | ||||||||||
2005 | Lencioni et al[13] | 206 | < 5 | 24 | 10 | 49 | 2.0 | 97 | 67 | 41 | 57 | 2 |
2005 | Tateishi et al[14] | 319 | < 5 | 28 | 8.7 | 60 | 4.0 | 95 | 78 | 54 | NA | 2 |
2005 | Chen et al[15] | 256 | < 8 | 2-69 | NA | NA | 2.4 | 83 | 67 | 41 | NA | 2 |
2007 | Choi et al[16] | 570 | < 5 | 30 | 11.8 | 52 | 1.9 | 95 | 70 | 58 | 77 | 2 |
2008 | Livraghi et al[17] | 216 | < 2 | 31 | 0.9 | NA | 1.8 | NA | 76 | 55 | NA | 2 |
2009 | N'Kontchou et al[18] | 235 | < 5 | 27 | 11.5 | 42 | 0.9 | NA | 60 | 40 | 48 |
RFA: Radiofrequency ablation;
Maximum diameter of tumor;
Mean follow-up period;
Rate of local tumor progression;
Rate of new recurrence including intrahepatic remote and extrahepatic metastasis;
Rate of major complications requiring additional hospitalization or therapeutic procedure;
Level of evidence.